Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1‐Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy

Purpose: We report our initial experience with whole body and dedicated prostate magnetic resonance imaging as a single examination to assess local recurrence and metastatic disease in patients with suspected recurrent prostate cancer after radical prostatectomy. Materials and Methods: In this institutional review board approved, retrospective, single center study 76 consecutive patients with clinically suspected recurrent prostate cancer following radical prostatectomy underwent combined whole body and dedicated prostate magnetic resonance imaging at a single session from October 2014 to January 2016. Scans were evaluated to detect disease in the prostate bed and regional nodes, and at distant sites. Comparison was made to other imaging tests, and prostate bed, node and bone biopsies performed within 90 days. Results: Whole body and dedicated prostate magnetic resonance imaging was completed successfully in all patients. Median prostate specific antigen was 0.36 ng/ml (range less than 0.05 to 56.12). Whole body and dedicated prostate magnetic resonance imaging identified suspected disease recurrence in 16 of 76 patients (21%), including local recurrence in the radical prostatectomy bed in 6, nodal metastases in 3, osseous metastases in 4 and multifocal metastatic disease in 3. In 43 patients at least 1 standard staging scan was done in addition to whole body and dedicated prostate magnetic resonance imaging. Concordance was demonstrated between the imaging modalities in 36 of 43 cases (84%). All metastatic lesions detected by other imaging tests were detected on magnetic resonance imaging. In addition, the magnetic resonance imaging modality detected osseous metastases in 4 patients with false‐negative findings on other imaging tests, including 2 bone scans and 3 computerized tomography scans. It also excluded osseous disease in 1 patient with positive 18F‐fluorodeoxyglucose positron emission tomography/computerized tomography and subsequent negative bone biopsy. Conclusions: Combined whole body and dedicated prostate magnetic resonance imaging is feasible in a clinical practice setting. It can provide incremental information compared to standard imaging in men with suspected prostate cancer recurrence after radical prostatectomy.

[1]  R. Daffner,et al.  MRI in the detection of malignant infiltration of bone marrow. , 1986, AJR. American journal of roentgenology.

[2]  S. Groshen,et al.  Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[3]  D. Gillatt,et al.  A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  Matthias Eiber,et al.  Whole‐body MRI including diffusion‐weighted imaging (DWI) for patients with recurring prostate cancer: Technical feasibility and assessment of lesion conspicuity in DWI , 2011, Journal of magnetic resonance imaging : JMRI.

[5]  R. Thompson,et al.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. , 2011, European urology.

[6]  O. Rouvière,et al.  Imaging of prostate cancer local recurrences: why and how? , 2010, European Radiology.

[7]  H. Almquist,et al.  18F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy , 2015, World Journal of Urology.

[8]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[9]  J. Moul.  Prostate specific antigen only progression of prostate cancer. , 2000, The Journal of urology.

[10]  William J Catalona,et al.  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. , 2004, The Journal of urology.

[11]  T. DeGrado,et al.  ORIGINAL ARTICLE: Pilot comparison of 18F‐fluorocholine and 18F‐fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer , 2010, Journal of medical imaging and radiation oncology.

[12]  Hedvig Hricak,et al.  Value of a standardized lexicon for reporting levels of diagnostic certainty in prostate MRI. , 2014, AJR. American journal of roentgenology.

[13]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[14]  Laurence Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[15]  A. Kao,et al.  Detecting Metastatic Pelvic Lymph Nodes by 18F-2-Deoxyglucose Positron Emission Tomography in Patients with Prostate-Specific Antigen Relapse after Treatment for Localized Prostate Cancer , 2003, Urologia Internationalis.

[16]  Thomas Wiegel,et al.  Guidelines on Prostate Cancer , 2013 .

[17]  P. Alken,et al.  The Difficult Stone Case: Definition and Management , 2001, European Urology.

[18]  D. Chan,et al.  Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .

[19]  M. Banerjee,et al.  Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. , 1998, The Journal of urology.

[20]  I. Floriani,et al.  Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. , 2008, AJR. American journal of roentgenology.

[21]  J. Moul,et al.  Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. , 2003, Urology.

[22]  N. V. As,et al.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. , 2016, European urology.

[23]  Laurence Collette,et al.  One‐step TNM staging of high‐risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all‐in‐one” imaging approach? , 2014, The Prostate.

[24]  C. Abbou,et al.  EAU guidelines on prostate cancer. , 2009, European urology.

[25]  E. Kauppila,et al.  Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial , 2016, Acta oncologica.

[26]  Valentina Taviani,et al.  Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer , 2015, The Journal of Nuclear Medicine.